Daniel Barber has been the CEO of Aquestive Therapeutics, Inc. since May 2022. With a solid background in management, he earned a B.S. in Management from Purdue University and has over 15 years of experience in the healthcare industry. Before...

Daniel Barber has been the CEO of Aquestive Therapeutics, Inc. since May 2022. With a solid background in management, he earned a B.S. in Management from Purdue University and has over 15 years of experience in the healthcare industry. Before stepping into his current role, he served as the Chief Operating Officer and was integral to the company’s FDA-approved product launches. His hands-on approach to leading strategy and development has helped drive the company’s internal pipeline expansion. In terms of financial alignment, Daniel’s compensation in 2023 was around $1.07 million, made up of a base salary of $600,000 and a performance bonus that reflected his success in achieving company goals. He also received a significant stock grant designed to tie his performance to shareholder value, demonstrating his belief in the company's growth potential. Daniel has shown active participation in insider trading in the past, making notable transactions amounting to millions, which illustrates his confidence in the company's prospects. Under his leadership, the board is focusing on innovative approaches to drug delivery, an area where he has brought extensive knowledge and insight. Overall, Daniel Barber combines a strong educational foundation and practical experience to lead Aquestive toward its ambitious goals.